Atorvastatin therapy significantly decreased the mean yellow score of coronary plaques compared to the control group (decreased from 2.03 to 1.13 vs increased from 1.67 to 1.99; p=0.002).
Cohort
Does atorvastatin improve coronary plaque color and morphology in patients with coronary artery disease?
31 patients with coronary artery disease (evaluating 145 coronary plaques)
Atorvastatin for 12 months
Comparison group (no atorvastatin) for 12 months
Change in coronary plaque color (mean yellow score) and complexity (mean disrupted score) evaluated by coronary angioscopy at 12 monthssurrogate
Atorvastatin therapy significantly reduces coronary plaque yellow score and disruption score over 12 months, providing direct angioscopic evidence of plaque stabilization.
OBJECTIVES: Changes in coronary plaque color and morphology by statin therapy were evaluated using coronary angioscopy. BACKGROUND: Coronary plaque stabilization by statin therapy has not been clarified in humans. METHODS: Thirty-one patients with coronary artery disease were divided into either the comparison group (n = 16) or the atorvastatin group (n = 15). Before treatment and 12 months after, the color and complexity of 145 coronary plaques were determined according to angioscopic findings. The yellow score of the plaque was defined as 0 (white), 1 (light yellow), 2 (yellow), or 3 (dark yellow), and its disrupted score was defined as 0 (smooth surface) or 1 (irregular surface) and as 0 (without thrombus) or 1 (with thrombus). In each patient, the mean yellow score and mean disrupted score were calculated. RESULTS: Mean low-density lipoprotein cholesterol (LDL-C) decreased by 45% in the atorvastatin group, whereas an increase of 9% was seen in the comparison group. The mean yellow score decreased from 2.03 to 1.13 in the atorvastatin group, whereas it increased from 1.67 to 1.99 in the comparison group. There was a good correlation between the change in the mean yellow score and the change in LDL-C levels (r = 0.81, p < 0.0001). The change in the mean yellow score and mean disrupted score differed significantly between the two groups (p = 0.002 and p = 0.03, respectively). CONCLUSIONS: This is the first report clarifying detailed changes in coronary plaque by statin in humans. This study indicated that lipid-lowering therapy changes plaque color and morphology and should then lead to coronary plaque stabilization.
Building similarity graph...
Analyzing shared references across papers
Loading...
Masamichi Takano
Kyoichi Mizuno
Shinya Yokoyama
Journal of the American College of Cardiology
Chiba Hokusou Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Takano et al. (Fri,) conducted a cohort in coronary artery disease (n=31). atorvastatin vs. comparison group was evaluated on change in mean yellow score and mean disrupted score (p=0.002). Atorvastatin therapy significantly decreased the mean yellow score of coronary plaques compared to the control group (decreased from 2.03 to 1.13 vs increased from 1.67 to 1.99; p=0.002).
www.synapsesocial.com/papers/69ee2ce29de2ebe49371004e — DOI: https://doi.org/10.1016/s0735-1097(03)00770-8